NASDAQ · Biotechnology · USD

Kezar Life Sciences, Inc. (KZR) Stock Analysis

Kezar Life Sciences, Inc. (KZR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KZR

$7.29

$0.00 (0.00%)

Last trade May 11, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KZR with… →

KZR Key Statistics

As of May 11, 2026

Trading

Open: $7.29
Previous Close: $7.29
52-Week Range: 3.53–7.55
Beta: 0.41

Valuation

Market Cap: $53.86M
P/E Ratio: unprofitable
EPS (ttm): −6.17

Financials (FY)

Profit margin: 0.00%
1-Year Return: +72.75%

Dividend and dates

Avg Volume: 87.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KZR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+15.90%
2025	−0.16%

As of May 11, 2026.

KZR Valuation vs Biotechnology Median

Median of 656 stocks

Metric	KZR	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Kezar Life Sciences, Inc. (KZR) is capitalised at $53.86M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 9 employees.

Over the past 52 weeks the price has ranged from $3.53 to $7.55. KZR last closed at $7.29 on May 11, 2026. The close was unchanged from the previous session. The latest close sits 106.32% above that 52-week low.

Financial Health

The reported profit margin is 0%. Trailing earnings per share are −6.17.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.41. Annualized volatility over the trailing 1 year is 66.66%. Over the trailing twelve months the price has returned +72.75%.

Growth & Income

No dividend is on file for KZR.

The record holds one complete calendar year, 2025, which returned −0.16%. 2026 is still running; the price is +15.90% year to date.

Peer Comparison

Kezar Life Sciences, Inc. (KZR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kezar Life Sciences, Inc.	KZR	$53.86M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Kezar Life Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 11, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Visit website →